This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical
Microsoft Unveils Software to Enhance Employee Productivity
by Zacks Equity Research
Microsoft Corp. (MSFT) recently launched its long awaited employee performance analysis software called Workplace Analytics.
Geron Stock Up Almost 40% So Far This Year After '16 Decline
by Zacks Equity Research
Geron Corporation's (GERN) shares have risen 38.7% this year so far, outperforming the Zacks classified Medical - Biomedical and Genetics industry, which rose 5.6%. This comes after a decline of more than 57% in 2016.
Cardiome's Partner SteadyMed Submits NDA for PAH Injection
by Zacks Equity Research
Cardiome Pharma Corp. (CRME) announced that its partner SteadyMed Ltd. (STDY) has submitted a new drug application (NDA) to the FDA for its lead candidate, Trevyent (treprostinil injection), for treatment of pulmonary arterial hypertension (PAH).
Alkermes Presents Phase III Data on Schizophrenia Candidate
by Zacks Equity Research
Alkermes plc (ALKS) announced positive preliminary top-line results from a phase III study, ENLIGHTEN-1, evaluating its schizophrenia candidate, ALKS 3831.
Arena Ends Study on Extended Release Formulation of PAH Drug
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA), announced that it has completed an early-stage study comparing the once-daily, extended release (XR) formulation of its experimental pulmonary arterial hypertension (PAH) candidate, ralinepag, with its twice-daily immediate release (IR) formulation.
Top Research Reports for JNJ, AT&T & Lockheed Martin
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), AT&T (T), and Lockheed Martin (LMT).
Aduro Starts Phase II Combo Study with CRS-207 & Keytruda
by Zacks Equity Research
Aduro Biotech, Inc. (ADRO) has announced initiation of a phase II study to evaluate a combination therapy of its lead candidate, CRS-207, in combination with Keytruda, for treatment of patients with pleural mesothelioma (MPM).
Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca
How to Interpret Big Oil's Support for a Carbon Tax
by Nilanjan Choudhury
Surprisingly, some of the biggest energy companies have joined the call advocating for a progressively rising carbon tax.
Better Days Ahead for the Pharma Sector?
by Arpita Dutt
Sales, R&D, strong results, and a higher number of FDA approvals.
Gilead's (GILD) HCV Drug Application Accepted in the EU
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.
Healthcare ETF (IYH) Hits New 52-Week High
by Sweta Killa
This healthcare ETF hit a new 52-week high. Are more gains in store for this ETF?
Here's Why Geron (GERN) is a Good Stock to Invest in Now
by Zacks Equity Research
Geron Corporation (GERN) is developing anti-cancer therapies based on telomerase inhibitors.
Fitch Sees Fastest Global Growth in 10 Years: ETFs To Buy
by Zacks Equity Research
Credit rating agency Fitch expects the global growth to reach 2.9% in 2017 and 3.1% in 2018.
Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US
by Zacks Equity Research
Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older
Zacks.com featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago
by Zacks Equity Research
Zacks.com featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago
J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study
by Zacks Equity Research
Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).
AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?
by Zacks Equity Research
AbbVie Inc. (ABBV) shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05.
Company News for June 19, 2017
by Zacks Equity Research
Companies in the News are: FNSR,JNJ,BHP,DOW,DD
J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use
by Zacks Equity Research
Johnson & Johnson (JNJ) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone.
J&J's Invokana Lowers Heart Issues, Raises Amputation Risk
by Zacks Equity Research
Johnson & Johnson (JNJ) announced data from a large CANVAS outcomes program, which demonstrated that its type II diabetes drug Invokana (canagliflozin) was successful in reducing the risks of heart attacks and strokes.
Amgen's Multiple Myeloma Drug Receives NICE Recommendation
by Zacks Equity Research
Amgen Inc. (AMGN) announced that Kyprolis gained recommendation from National Institute for Health and Care Excellence (NICE) in combination with dexamethasone for the treatment of relapsed multiple myeloma.
J&J Announces EU Regulatory Approval for Actelion Deal
by Zacks Equity Research
Johnson & Johnson (JNJ) has received a regulatory approval from the European Commission (EC), thus completing all necessary formalities to close the pending acquisition of Swiss biopharmaceutical company, Actelion Ltd.
World Bank Foresees 7-Year High Global Growth: ETFs to Buy
by Zacks Equity Research
The World Bank has said that the global economy will grow at 2.9% in 2018, up from 2.7% this year.